Back

Moderna shares jump 8.18% as cancer vaccine rally pushes monthly gain above 100%

Verifying
  • Moderna and Merck reported Phase 3 INTerpath-001 results for high-risk melanoma patients.
  • 8.18%: Moderna shares reached $157.53 Thursday, extending their trailing-month gain above 100%.
  • The companies are advancing nine additional trials across melanoma, lung, bladder and kidney cancers.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.